Correlation between PAFAH1B3 Expression Level and Risk of Disease Progression After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 31; no. 2; p. 448
• Main Authors: Gu, Zhe-Yun, Tao, Jian, Cai, Yi-Feng, Wang, Ling
• Format: Journal Article
• Language: Chinese
• Published: China 01.04.2023
• Subjects: 1-Alkyl-2-acetylglycerophosphocholine Esterase - genetics; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma - drug therapy; Prognosis; Retrospective Studies; Transplantation, Autologous; multiple myeloma; platelet-activating factor acetylhydrolase 1B3; prognosis; progression-free survival
• ISSN: 1009-2137
• DOI: 10.19746/j.cnki.issn.1009-2137.2023.02.020

To investigate the association between the expression level of platelet-activating factor acetylhydrolase 1B3 ( ) gene in bone marrow CD138 cells of patients with multiple myeloma (MM) treated with autologous hematopoietic stem cell transplantation (AHSCT) and the prognosis within 2 years. 147 MM patients treated with AHSCT in The First and The Second Affiliated Hospital of Nantong University from May 2014 to May 2019 were included in the study. Expression level of mRNA in bone marrow CD138 cells of the patients was detected. Patients with disease progression or death during 2 years of follow-up were included in progression group, and the rest were included in good prognosis group. After comparing the clinical data and mRNA expression levels of the two groups, the patients were divided into high expression group and low expression group based on the median mRNA expression level of the enrolled patients. Progression-free survival rate (PFSR) between the two groups was compared by the Kaplan-Meier method. The r